Prosecution Insights
Prosecution Insights
34 pending office actions • 7 clients • 29 examiners • 22 art units • 0 of 34 (0%) have an AI response strategy ready • 48 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 13 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 13 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (3%) |
| §103 only | 7 (21%) |
| §102 only | 1 (3%) |
| §112 only | 5 (15%) |
| Double-patenting only | 6 (18%) |
| Double-patenting + other | 6 (18%) |
| Multi-statute (no §101) | 5 (15%) |
| No statute on record | 3 (9%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| AUDET, MAURY A | 2 | 50.0% | +23.8% |
| WEN, SHARON X | 2 | 56.8% | +32.8% |
| HUYNH, PHUONG N | 2 | 65.7% | +53.6% |
| HADDAD, MAHER M | 2 | 50.5% | +53.9% |
| OUSPENSKI, ILIA I | 2 | 77.5% | +20.4% |
| POPA, ILEANA | 1 | 21.5% | +14.6% |
| PIPIC, ALMA | 1 | 54.3% | +55.4% |
| CABRAL, ROBERT S | 1 | 62.6% | +32.4% |
| SABILA, MERCY HELLEN | 1 | 57.6% | +45.9% |
| BRETZ, COREY LANE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18512687 | METHODS, CELLS & ORGANISMS | HOLLAND, PAUL J | 140d overdue |
| 18358601 | THROMBIN CLEAVABLE LINKER WITH XTEN AND ITS USES THEREOF | BEANE, RANDALL L | 37d overdue |
| 18016625 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | ROZOF, TIMOTHY R | 6d |
| 18045995 | FGFR3 ANTIBODIES AND METHODS OF USE | ALLEN, MARIANNE P | 26d |
| 18890983 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | POPA, ILEANA | — |
| 18729020 | LIPIDIC COMPOUNDS, AND USES THEREOF | PIPIC, ALMA | — |
| 18626784 | TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY | BRETZ, COREY LANE | — |
| 18186856 | MRNA THERAPEUTIC COMPOSITIONS AND USE TO TREAT DISEASES AND DISORDERS | SINGH, ANOOP KUMAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17727309 | ANTI-ICOS ANTIBODIES | OUSPENSKI, ILIA I | 204d overdue |
| 18364906 | ANTIBODIES, USES & METHODS | HADDAD, MAHER M | 7d |
| 17725228 | SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD | OUSPENSKI, ILIA I | 12d |
| 18459995 | ANTIBODIES, COMBINATIONS COMPRISING ANTIBODIES, BIOMARKERS, USES & METHODS | HADDAD, MAHER M | 26d |
| 18407331 | METHODS FOR REDUCING OR ELIMINATING THE NEED FOR LIPOPROTEIN APHERESIS IN PATIENTS WITH HYPERLIPIDEMIA BY ADMINISTERING ALIROCUMAB | WEN, SHARON X | 30d |
| 17291937 | 2,5-DIOXOPIPERAZINE LIPIDS WITH INTERCALATED ESTER, THIOESTER, DISULFIDE AND ANHYDRIDE MOIEITIES | AUDET, MAURY A | 79d |
| 18890983 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | POPA, ILEANA | — |
| 18888602 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVES | AUDET, MAURY A | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Sanofi | 10 |
| TRANSLATE BIO, INC. | 7 |
| GENZYME CORPORATION | 5 |
| REGENERON PHARMACEUTICALS, INC. | 4 |
| Kymab | 4 |
| Bioverativ Therapeutics | 3 |
| KYMAB LIMITED | 1 |
| Art Unit | Apps |
|---|---|
| 1641 | 5 |
| 1654 | 3 |
| 1643 | 3 |
| 1644 | 2 |
| 1617 | 1 |
| 1614 | 1 |
| 1638 | 1 |
| 1656 | 1 |
| 1674 | 1 |
| 1637 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18890983 | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR DELIVERY OF NUCLEIC ACIDS | Translate Bio, Inc. | POPA, ILEANA | §103 | Non-Final OA | — | Pending | Sep 20, 2024 | |
| 18888602 | STABILIZED PHARMACEUTICAL FORMULATIONS OF INSULIN ANALOGUES AND/OR INSULIN DERIVATIVES | Sanofi | AUDET, MAURY A | 1654 | §112 | Non-Final OA | — | Pending | Sep 18, 2024 |
| 18729020 | LIPIDIC COMPOUNDS, AND USES THEREOF | Sanofi | PIPIC, ALMA | 1617 | §102§112 | Non-Final OA | — | Pending | Jul 15, 2024 |
| 18753746 | PROCESS OF PREPARING MRNA-LOADED LIPID NANOPARTICLES | Translate Bio, Inc. | CABRAL, ROBERT S | 1614 | §102 | Non-Final OA | — | Pending | Jun 25, 2024 |
| 18656168 | METHODS OF TREATING HEMOPHILIA A | BIOVERATIV THERAPEUTICS INC. | SABILA, MERCY HELLEN | §102§103DP | Non-Final OA | — | Pending | May 06, 2024 | |
| 18626784 | TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY | Genzyme Corporation | BRETZ, COREY LANE | DP | Non-Final OA | — | Pending | Apr 04, 2024 | |
| 18440711 | BACULOVIRUS EXPRESSION SYSTEM | BIOVERATIV THERAPEUTICS INC. | JACKSON III, WALTER | 1638 | §103 | Non-Final OA | — | Pending | Feb 13, 2024 |
| 18407331 | METHODS FOR REDUCING OR ELIMINATING THE NEED FOR LIPOPROTEIN APHERESIS IN PATIENTS WITH HYPERLIPIDEMIA BY ADMINISTERING ALIROCUMAB | Regeneron Pharmaceuticals, Inc. | WEN, SHARON X | 1641 | §103Other | Non-Final OA | 30d | Pending | Jan 08, 2024 |
| 18512687 | METHODS, CELLS & ORGANISMS | Kymab Limited | HOLLAND, PAUL J | 1656 | §102§103Other | Final Rejection | 140d overdue | Pending | Nov 17, 2023 |
| 18495182 | METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST | Regeneron Pharmaceuticals, Inc. | MERTZ, PREMA MARIA | 1674 | DP | Final Rejection | — | Pending | Oct 26, 2023 |
| 18286029 | IMPROVED COMPOSITIONS FOR DELIVERY OF MRNA | Translate Bio, Inc. | ZARA, JANE J | 1637 | DP | Non-Final OA | — | Pending | Oct 06, 2023 |
| 18470507 | METHODS FOR QUANTIFYING DRUG CONCENTRATION IN A PRODRUG COMPOSITION | Genzyme Corporation | ADAMS, MICHELLE | 1797 | DP | Final Rejection | — | Pending | Sep 20, 2023 |
| 18463047 | HYPERGLYCOSYLATED BINDING POLYPEPTIDES | Genzyme Corporation | HUYNH, PHUONG N | 1641 | §112 | Non-Final OA | — | Pending | Sep 07, 2023 |
| 18459995 | ANTIBODIES, COMBINATIONS COMPRISING ANTIBODIES, BIOMARKERS, USES & METHODS | Kymab Limited | HADDAD, MAHER M | 1641 | §103 | Final Rejection | 26d | Pending | Sep 01, 2023 |
| 18364906 | ANTIBODIES, USES & METHODS | Kymab Limited | HADDAD, MAHER M | 1641 | Other | Final Rejection | 7d | Pending | Aug 03, 2023 |
| 18358601 | THROMBIN CLEAVABLE LINKER WITH XTEN AND ITS USES THEREOF | BIOVERATIV THERAPEUTICS INC. | BEANE, RANDALL L | 1654 | §103§112Other | Final Rejection | 37d overdue | Pending | Jul 25, 2023 |
| 18319279 | SITE-SPECIFIC GLYCOENGINEERING OF TARGETING MOIETIES | Genzyme Corporation | PUTTLITZ, KARL J | 1646 | §103§112DP | Non-Final OA | — | Pending | May 17, 2023 |
| 18308778 | MULTIFUNCTIONAL NATURAL KILLER (NK) CELL ENGAGERS BINDING TO NKp46 AND CD123 | Sanofi | HAM, JIEUN | 1643 | §103§112DP | Non-Final OA | — | Pending | Apr 28, 2023 |
| 18186856 | MRNA THERAPEUTIC COMPOSITIONS AND USE TO TREAT DISEASES AND DISORDERS | Translate Bio, Inc. | SINGH, ANOOP KUMAR | 1632 | §103§112 | Non-Final OA | — | Pending | Mar 20, 2023 |
| 18185465 | PSEUDOFAB-BASED MULTISPECIFIC BINDING PROTEINS | Sanofi | HUYNH, PHUONG N | 1641 | Other | Final Rejection | — | Pending | Mar 17, 2023 |
| 17969033 | METHODS FOR TREATING PRURIGO NODULARIS BY ADMINISTERING AN IL-4R ANTAGONIST | Regeneron Pharmaceuticals, Inc. | NATARAJAN, MEERA | 1643 | §103 | Non-Final OA | 4d overdue | Pending | Mar 02, 2023 |
| 18016625 | LIPIDIC COMPOUNDS COMPRISING AT LEAST ONE TERMINAL RADICAL OF FORMULA -NH-CX-A OR -NH-CX-NH-A, COMPOSITIONS CONTAINING THEM AND USES THEREOF | Sanofi Pasteur | ROZOF, TIMOTHY R | 1625 | §102§112 | Final Rejection | 6d | Pending | Jan 17, 2023 |
| 18052600 | RESPIRATORY SYNCTIAL VIRUS RNA VACCINE | Sanofi | PYLA, EVELYN Y | 1633 | §112DP | Non-Final OA | — | Pending | Nov 04, 2022 |
| 18045995 | FGFR3 ANTIBODIES AND METHODS OF USE | Genzyme Corporation | ALLEN, MARIANNE P | 1647 | §101§112 | Final Rejection | 26d | Pending | Oct 12, 2022 |
| 17801099 | PROPIONIBACTERIUM ACNES PROPHYLACTIC AND THERAPEUTIC IMMUNE TREATMENT | Sanofi Pasteur Inc. | GRASER, JENNIFER E | 1645 | §112 | Final Rejection | 70d | Pending | Aug 19, 2022 |
| 17871121 | METHODS FOR PURIFICATION OF MESSENGER RNA | Translate Bio, Inc. | BRANDSEN, BENJAMIN MICHAEL | 1693 | §103Other | Final Rejection | — | Pending | Jul 22, 2022 |
| 17782930 | USE OF A PCSK9 INHIBITOR TO TREAT HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | Sanofi Biotechnology | STONEBRAKER, ALYSSA RAE | 1642 | DP | Final Rejection | — | Pending | Jun 06, 2022 |
| 17778935 | A METHOD OF FORMING A CONJUGATE OF A SULFONAMIDE AND A POLYPEPTIDE | Sanofi | DICKINSON, PAUL W | 1618 | §112 | Non-Final OA | — | Pending | May 23, 2022 |
| 17727309 | ANTI-ICOS ANTIBODIES | Kymab Limited | OUSPENSKI, ILIA I | 1644 | DP | Final Rejection | 204d overdue | Pending | Apr 22, 2022 |
| 17725228 | SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD | Kymab Limited | OUSPENSKI, ILIA I | 1644 | Other | Non-Final OA | 12d | Pending | Apr 20, 2022 |
| 17344535 | METHODS FOR PURIFICATION OF MESSENGER RNA | Translate Bio, Inc. | LU, FRANK WEI MIN | 1683 | §103§112DP | Non-Final OA | — | Pending | Jun 10, 2021 |
| 17291937 | 2,5-DIOXOPIPERAZINE LIPIDS WITH INTERCALATED ESTER, THIOESTER, DISULFIDE AND ANHYDRIDE MOIEITIES | Translate Bio, Inc. | AUDET, MAURY A | 1654 | §112 | Non-Final OA | 79d | Pending | May 06, 2021 |
| 17185469 | METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER BY MEASURING THE LEVEL OF A PLASMA BIOMARKER | Sanofi | WEN, SHARON X | 1600 | §103DP | Non-Final OA | — | Pending | Feb 25, 2021 |
| 17183904 | COMPOSITIONS COMPRISING IL6R ANTIBODIES FOR THE TREATMENT OF UVEITIS AND MACULAR EDEMA AND METHODS OF USING SAME | Regeneron Pharmaceuticals, Inc. | FAUST, AMBER KATHLEEN | 1643 | §103 | Non-Final OA | 33d | Pending | Feb 24, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial